Keyword: Ironwood Pharmaceuticals
Cyclerion Therapeutics was just a few months on from its spinout from Ironwood Pharma when it was forced to abandon a key indication for one of its lead drugs—soluble guanylate cyclase (sGC) stimulator praliciguat—prompting it to ax more than one-fifth of its workforce.
Pear Therapeutics is expanding its app-based platform to conditions outside of the brain and mental health through a GI-focused deal with Ironwood.
Cyclerion Therapeutics will lay off 30 employees after one of its lead programs fell short in heart failure and diabetic kidney disease trials.
Rare disease biotech Cyclerion has poached Shire’s ex-head of R&D, Andy Busch, Ph.D., as its new chief innovation officer, less than 18 months after he joined the company from his long stint at Bayer.
Ironwood will walk away from its deal for AstraZeneca’s billion-dollar gout treatment lesinurad, following poor market performance.
Ironwood plans to split into two independent companies, spinning off some of its R&D work into a yet-unnamed business in the first half of 2019.
Ironwood Pharmaceuticals unveiled promising topline data from phase 2a trials investigating its sGC stimulator in patients with Type 2 diabetes and hypertension.
CSO Hayden will leave as Teva restructures, Bayer R&D reorg sees Moeller in and Busch out for Shire, Shire and Biogen get experienced CFOs.
Ardelyx now has a second positive phase 3 trial for its constipation-predominant irritable bowel syndrome drug tenapanor.
R&D chief Narsimhan will replace retiring Jimenez as Novartis CEO, Stada names its fourth CEO in less than two years, Vertex poaches CFO from Ironwood.